Teleflex Incorporated (NYSE: TFX) announced on October 12, 2026, that it had completed enrollment in the BIOMAG-LL clinical study, with 102 patients recruited across 14 European centers to evaluate longer versions of its Freesolve sirolimus-eluting resorbable magnesium scaffold. The prospective, single-arm investigation is assessing 35 mm and 40 mm scaffold lengths for treating newly developed coronary artery lesions up to 38 mm, with the primary clinical assessment focused on target lesion failure at 12 months.
The enrollment milestone represents progress toward extending Freesolve into longer coronary lesions, where physicians may otherwise need multiple devices or overlapping stents to achieve adequate vessel coverage. Freesolve is designed to provide temporary mechanical support after percutaneous coronary intervention before its magnesium framework gradually resorbs. However, BIOMAG-LL has not yet reported its clinical outcomes, and the completion of recruitment does not establish that the longer devices are safe, effective or superior to permanent drug-eluting stents.
The distinction is particularly important because Freesolve is already commercially available in countries accepting its existing CE marking, while the new 35 mm and 40 mm configurations are being investigated to support expansion of the authorized size range. The currently marketed portfolio includes scaffold lengths from 13 mm to 30 mm, meaning BIOMAG-LL addresses a specific extension of the technology rather than its initial introduction into clinical practice.
The development also comes as Teleflex advances two larger randomized clinical programmes, BIOMAG-II and BIOMAG-III, comparing Freesolve with Abbott Laboratories’ Xience drug-eluting stent. Together, these studies will help determine whether resorbable magnesium scaffolds can offer competitive coronary outcomes while avoiding the lifelong presence of a permanent metallic implant. The potential clinical benefit of leaving less permanent material behind remains an important scientific hypothesis, not an advantage established by the latest enrollment announcement.
Why are 35 mm and 40 mm Freesolve scaffolds important for treating longer coronary lesions?
Long coronary artery lesions present additional challenges during percutaneous coronary intervention because disease can extend across substantial segments of the vessel. Physicians must achieve adequate lesion coverage while maintaining blood flow and limiting injury to the surrounding arterial wall. Where a single device cannot cover the affected segment, treatment may require multiple stents or scaffolds, sometimes with overlapping sections.
Overlapping implants introduce additional layers of material into the treated artery and can increase procedural complexity. They may also create challenges involving device expansion, vessel geometry and subsequent healing, particularly in arteries with diffuse atherosclerosis or significant calcification. The clinical consequences depend on lesion characteristics, device selection and implantation technique rather than overlap alone.
Teleflex is investigating whether longer Freesolve scaffolds can provide an alternative to multiple shorter implants in appropriately selected patients. The 35 mm and 40 mm versions are intended to complement the existing scaffold size matrix, which offers diameters of 2.5 mm, 3.0 mm, 3.5 mm and 4.0 mm. Extending the available lengths could give interventional cardiologists more flexibility when selecting devices for longer lesions.
The potential benefit is not simply reducing the number of implants used during a procedure. A longer scaffold must maintain adequate radial support, consistent expansion and appropriate drug delivery across a greater arterial segment. It must also accommodate anatomical characteristics such as vessel curvature, diameter changes and lesion composition.
Teleflex has suggested that longer resorbable scaffolds could offer an alternative to drug-coated balloons in selected situations where temporary mechanical support is required. However, BIOMAG-LL is not designed to demonstrate superiority over drug-coated balloons, and the announcement does not establish reduced procedure times or fewer complications. Those potential advantages would require appropriate comparative evidence.
What will the 102-patient BIOMAG-LL study establish about safety and clinical performance?
BIOMAG-LL, registered as NCT07091682, is a prospective, international, multicenter, open-label, single-arm clinical investigation. The study was originally designed to enroll approximately 100 patients, with Teleflex now confirming that 102 participants have been recruited across 14 European centers. It is evaluating Freesolve scaffolds measuring 35 mm and 40 mm in patients with previously untreated coronary lesions up to 38 mm long.
The primary endpoint is target lesion failure at 12 months following the index procedure. This composite outcome includes cardiac death, target-vessel myocardial infarction and clinically driven target lesion revascularization. The latter refers to a repeat procedure performed because the previously treated lesion requires further intervention.
Target lesion failure provides a clinically relevant measure because it captures serious events and the durability of the initial coronary intervention. However, composite endpoints require careful interpretation, since their individual components can differ substantially in severity and frequency. A low overall failure rate may be driven largely by fewer repeat procedures, for example, without necessarily demonstrating differences in cardiac mortality.
The study includes scheduled follow-up assessments at one, six, 12, 36 and 60 months after implantation. This extended observation period is important because resorbable scaffolds undergo changes in mechanical structure and biological interaction as their material degrades. Longer-term follow-up can help investigators identify complications or performance changes that may not become apparent during the first year.
A pharmacokinetic substudy is also planned to evaluate systemic exposure to sirolimus released from the scaffold. The registered protocol describes an intended group of 15 patients undergoing blood sampling during the first seven days after implantation. Those measurements can contribute to understanding drug exposure, although pharmacokinetic findings cannot independently establish clinical efficacy.
The principal limitation is the absence of a randomized comparator within BIOMAG-LL. The study can characterize outcomes associated with the longer Freesolve devices in its enrolled population, but it cannot establish that they perform better than permanent drug-eluting stents or drug-coated balloons. Its contribution will be most useful when interpreted alongside the larger randomized Freesolve development programme.
How does Freesolve’s magnesium scaffold technology differ from permanent drug-eluting stents?
Freesolve, also identified in clinical research as the third-generation Drug-Eluting Resorbable Magnesium Scaffold or DREAMS 3G, combines temporary mechanical support with local delivery of sirolimus. The device uses a proprietary magnesium alloy structure coated with a biodegradable polymer containing the antiproliferative medicine. Sirolimus is intended to limit excessive tissue growth that could narrow the treated artery after intervention.
Conventional metallic drug-eluting stents provide a permanent structural framework that remains within the artery after implantation. They have extensive randomized clinical evidence supporting their use and have undergone substantial improvements in design, strut thickness and drug delivery. Their permanent presence, however, has encouraged research into whether temporary scaffolding could provide comparable early support while reducing the amount of material remaining in the vessel.
Freesolve is engineered to undergo resorption over approximately 12 months. Intravascular imaging from the earlier BIOMAG-I study demonstrated approximately 99% resorption of the magnesium scaffold structure at 12 months, although the radiopaque markers used to identify its position are not resorbable. This supports the device’s material-resorption characteristics without proving that the treated artery returns to its original biological or mechanical state.
The technology has evolved through successive generations intended to improve radial strength, scaffold geometry and degradation characteristics. The third-generation design incorporates thinner struts than earlier versions and has been developed to maintain mechanical support during the period when the artery is healing. These engineering improvements are relevant because insufficient early support could compromise vessel patency before resorption is complete.
The clinical rationale is that an artery may eventually remain open without requiring a permanent metallic framework at the original treatment site. Nevertheless, removing the scaffold material does not automatically restore normal vessel function or eliminate future atherosclerotic disease. The longer-term clinical benefits of this approach must be established through comparative outcomes rather than inferred from successful material degradation.
What do the earlier BIOMAG-I clinical results demonstrate about Freesolve durability?
The BIOMAG-I first-in-human study provides the most mature publicly reported clinical follow-up for Freesolve. It enrolled 116 patients with 117 coronary lesions and evaluated the third-generation magnesium scaffold in symptomatic coronary artery disease. The investigation primarily involved shorter lesions, with eligibility extending to lesions measuring no more than 28 mm, making its population different from the longer-lesion focus of BIOMAG-LL.
At six months, investigators reported mean in-scaffold late lumen loss of 0.21 mm. Late lumen loss measures the reduction in the vessel’s internal diameter after treatment and is commonly used to assess restenosis following coronary intervention. The result provided early angiographic evidence supporting the scaffold’s performance, although it did not establish superiority over contemporary permanent drug-eluting stents.
Peer-reviewed three-year results subsequently reported a Kaplan-Meier estimated target lesion failure rate of 3.5%, with a 95% confidence interval of 1.3% to 9.0%. Four clinically driven target lesion revascularizations were reported, while investigators recorded no cardiac deaths, target-vessel myocardial infarctions or definite, probable or possible scaffold thrombosis during the reported follow-up. The findings were encouraging but came from a relatively small, uncontrolled study.
In May 2026, Teleflex presented additional four-year BIOMAG-I follow-up at EuroPCR, reporting that target lesion failure remained at 3.5% and that no new clinical events had occurred between years two and four. The company interpreted this as evidence of sustained performance after scaffold resorption. The result adds long-term information, but the small sample size limits the ability to identify uncommon complications or establish outcomes across more complex coronary lesions.
BIOMAG-LL will therefore test whether the earlier findings remain relevant when the technology is extended to longer scaffold configurations. Longer lesions may have different risks involving plaque burden, vessel geometry and restenosis, making direct extrapolation from the first-in-human population inappropriate. The absence of new late events in BIOMAG-I provides a useful foundation, but it does not guarantee equivalent performance in BIOMAG-LL.
Why does the history of bioresorbable coronary scaffolds make randomized evidence essential?
The concept of replacing permanent coronary implants with temporary scaffolding has attracted considerable research interest, but its clinical development history has included significant setbacks. Earlier polymer-based bioresorbable scaffolds were introduced with the expectation that eventual material disappearance might provide long-term benefits. Subsequent randomized evidence showed that some of those devices carried higher risks than established permanent drug-eluting stents.
Abbott Laboratories’ Absorb bioresorbable vascular scaffold became a prominent example of these challenges. A pooled analysis of four randomized ABSORB trials involving 3,389 patients found that three-year target lesion failure occurred in 11.7% of patients receiving the polymer-based scaffold, compared with 8.1% receiving metallic everolimus-eluting stents. Device thrombosis rates were also higher, at 2.4% versus 0.6%.
The United States Food and Drug Administration previously warned about the elevated adverse cardiac event rates observed with Absorb, particularly in certain smaller vessels. Abbott subsequently discontinued commercial sales of the device in 2017. These historical findings continue to shape how clinicians evaluate newer bioresorbable coronary technologies.
Freesolve differs materially from Absorb because it uses a magnesium alloy rather than the earlier polymer scaffold architecture. Its degradation characteristics, strut design and mechanical properties are also different, meaning historical complications cannot simply be assumed to occur at identical rates with Freesolve. Equally, the differences in technology do not automatically establish that the new device has overcome every limitation associated with bioresorbable scaffolding.
Randomized clinical evidence is therefore particularly important for determining whether Freesolve can produce outcomes comparable to contemporary permanent stents. The appropriate assessment must consider early procedural performance, repeat revascularization, myocardial infarction and scaffold thrombosis, as well as longer-term events after resorption. BIOMAG-LL contributes evidence for longer-device configurations, but the larger randomized trials are better positioned to address comparative clinical performance.
How will BIOMAG-II and BIOMAG-III determine Freesolve’s competitive position?
Teleflex is pursuing a substantial randomized clinical development programme alongside BIOMAG-LL. In June 2026, the company announced that BIOMAG-II had completed enrollment ahead of schedule, recruiting 1,861 patients across 20 countries in Europe and Asia Pacific. The study is comparing Freesolve with Abbott Laboratories’ Xience drug-eluting stent, using target lesion failure at 12 months as its principal outcome.
The randomized comparison is important because Xience represents an established permanent drug-eluting stent platform supported by extensive clinical evidence. A successful result would provide stronger evidence of Freesolve’s performance relative to a recognized treatment option than could be obtained from single-arm studies alone. Teleflex previously indicated that a BIOMAG-II data readout was expected in late 2027, although this remains a company forecast rather than a guaranteed reporting date.
BIOMAG-III extends the randomized development programme into the United States and additional international markets. Enrollment began in June 2026, with the first United States implantation performed at MedStar Health in Washington, D.C. The pivotal investigation is designed to enroll 1,859 patients at up to 120 sites worldwide, including as many as 60 sites in the United States.
Like BIOMAG-II, BIOMAG-III compares Freesolve against Xience using target lesion failure at 12 months. Importantly, the investigation includes scaffold lengths up to 40 mm, allowing the longer configurations to contribute to the broader clinical evidence package. The study’s results are intended to support future regulatory applications, including potential United States market entry.
Together, the studies address different but complementary questions. BIOMAG-LL focuses specifically on safety and clinical performance with longer Freesolve configurations, while BIOMAG-II and BIOMAG-III provide randomized evidence against a permanent drug-eluting stent. The findings will need to be interpreted according to each study’s patient population, endpoint definitions and statistical analysis rather than combined into an unsupported claim of superiority.
What does BIOMAG-LL enrollment mean for European CE marking and United States approval?
Freesolve received its original European CE marking in February 2024 and is commercially available in countries that accept the applicable certification, subject to local indications and availability. The currently offered configurations include scaffold lengths of 13 mm, 18 mm, 22 mm, 26 mm and 30 mm. The longer 35 mm and 40 mm versions evaluated in BIOMAG-LL are part of a planned size expansion requiring supporting clinical and regulatory evidence.
The study registration identifies the investigation as a premarketing assessment intended to support CE certification of those longer configurations. Completion of enrollment is an operational milestone within that process, not evidence that the expanded sizes have received the necessary conformity assessment. Regulatory review will need to consider the relevant clinical outcomes, device documentation and applicable European medical device requirements.
United States regulatory status remains separate. Freesolve is investigational in the United States and is not approved for commercial sale there. BIOMAG-III is being conducted under an investigational device framework to generate evidence for future regulatory consideration, but initiation of a pivotal trial does not establish that marketing approval will be granted.
The geographic distinction has practical commercial implications. Teleflex can continue to develop Freesolve within its existing CE-marked markets while simultaneously generating evidence for expanded configurations and a potential United States introduction. However, commercialization of the longer sizes will depend on the applicable regulatory decisions and the exact indications permitted in each jurisdiction.
A broader size matrix could improve the product’s utility in European catheterization laboratories by expanding the range of lesions physicians can consider treating. That potential advantage still depends on confirming that the longer devices perform adequately and can be supplied consistently. Additional clinical evidence may influence physician confidence, but regulatory certification alone would not establish widespread adoption.
Why is Freesolve strategically important after Teleflex’s BIOTRONIK acquisition?
Freesolve became part of Teleflex’s portfolio following its acquisition of substantially all of BIOTRONIK’s Vascular Intervention business in 2025. The transaction closed on June 30, 2025, and added coronary and peripheral intervention technologies to Teleflex’s existing product range. Freesolve provides the company with exposure to resorbable coronary scaffolding alongside more established stents, balloons and other interventional devices.
The acquisition was originally announced with consideration of approximately €760 million, subject to adjustments, while Teleflex subsequently reported a net initial cash payment of €704.3 million. The purchase was not solely an investment in Freesolve, as it included a substantially broader portfolio of commercial medical devices. Nevertheless, the scaffold programme represents one of the acquired business’s longer-term development opportunities.
Teleflex’s latest quarterly results illustrate the wider commercial context. The company reported second-quarter 2026 revenue from continuing operations of $570.3 million, an increase of 28.9% on a reported basis. On a pro forma adjusted constant currency basis, which accounts for acquisition effects and other adjustments, growth was considerably lower at 4.7%.
Within the Interventional product category, second-quarter revenue reached $211.9 million. However, pro forma adjusted constant currency sales declined approximately 1.0% compared with the prior-year period, demonstrating why acquisition-driven reported growth must be distinguished from underlying commercial performance. Management also acknowledged that integration of the acquired BIOTRONIK business was taking longer than expected.
Teleflex reduced its full-year 2026 revenue growth guidance while maintaining investment in selected innovation programmes, including Freesolve. The company indicated that BIOMAG-II enrollment, BIOMAG-III initiation and longer-term BIOMAG-I findings represented progress within its interventional development pipeline. These milestones support the programme’s advancement, but their near-term impact on consolidated revenue is not separately disclosed.
Freesolve therefore offers a potential medium- to long-term portfolio opportunity rather than an immediate earnings catalyst directly attributable to BIOMAG-LL enrollment. Commercial value will depend on expanding authorized uses, generating comparative evidence and establishing sufficient physician adoption. The company has not disclosed a standalone Freesolve revenue forecast or market share target that would support a precise financial contribution estimate.
What clinical milestones will determine whether longer Freesolve scaffolds reach broader commercial use?
The immediate priority following completion of BIOMAG-LL enrollment is collecting and evaluating the scheduled follow-up data. The study’s primary 12-month target lesion failure assessment will provide the central clinical evidence for the longer configurations. The registered timetable previously estimated primary completion in June 2027, although the actual reporting schedule will depend on participant follow-up, data validation and analysis.
Clinical interpretation will need to examine more than the composite endpoint alone. Individual rates of cardiac death, target-vessel myocardial infarction and clinically driven revascularization will help establish the nature of any observed treatment failures. Information about scaffold thrombosis, procedural performance and adverse events will also be important when evaluating the longer devices.
The extended three-year and five-year follow-up periods should provide additional evidence after the magnesium scaffold has substantially resorbed. This is relevant because a central proposition of resorbable coronary technology concerns the possibility of avoiding complications associated with permanent implant material over time. Demonstrating a favorable long-term safety profile will require sufficiently mature clinical observations, particularly in patients with complex coronary disease.
The larger randomized trials will be equally consequential. BIOMAG-II is expected to provide comparative evidence before BIOMAG-III completes its broader international development programme. Whether the technology achieves its intended regulatory and clinical objectives will depend on the prespecified analyses rather than isolated numerical comparisons with historical stent studies.
Commercial adoption will subsequently require cardiologists and hospitals to evaluate Freesolve within existing percutaneous coronary intervention practices. Device selection, lesion preparation, imaging requirements, procedural training and acquisition costs may all influence how widely the technology is used. Longer scaffold availability could improve procedural flexibility, but the company must demonstrate that the resulting clinical and operational benefits justify adoption.
Teleflex’s latest enrollment milestone establishes that its longer Freesolve configurations have progressed through an important phase of clinical recruitment. Earlier BIOMAG-I findings provide encouraging evidence regarding scaffold resorption and long-term outcomes in a smaller patient population, while BIOMAG-LL is designed to test performance in longer lesions that may present additional procedural challenges.
The most consequential next step is demonstrating that the 35 mm and 40 mm scaffolds achieve acceptable 12-month clinical outcomes without introducing safety concerns associated with longer treated segments. Beyond that, BIOMAG-II and BIOMAG-III must establish how Freesolve performs against contemporary permanent drug-eluting stents in randomized comparisons. Those results will determine whether the technology can progress from a differentiated resorbable scaffold platform into a more broadly adopted alternative within coronary intervention.
